Bolt Biotherapeutics Inc. Common Stock (BOLT)

FairStock Score: 66/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable competitive advantages, honest accounting, and a margin of safety. Bolt Biotherapeutics is a clinical-stage cancer immunotherapy company with 23 employees and two named pipeline programs, BDC-4182 and BDC-3042. But its financial record is not that of a business; it is that of a research project funded by investors. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was just $5,000 and net loss was $7.7 million. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $26,000 and net loss was $7.2 million. For FY2025, the year ended 2025-12-31, revenue was $7.7 million and net loss was $33.4 million. FY2024 revenue was $7.7 million with a $63.1 million net loss, and FY2023 revenue was $7.9 million with a $69.2 million net loss. The loss narrowed in FY2025, but revenue in the latest filed quarters has collapsed to almost nothing. At the 2026-10-13 close of $4.28 and an $8.3 million market cap, FairStock calculations show P/B 0.65, P/E -0.26, ROE -111.65%, ROCE -30.73%, D/E 1.71, and FCF yield -382.1%. Trailing free cash flow is -$31.5 million. FairStock's Piotroski score is 1/9 and Altman Z-score is -16.57, both warning signs. A low P/B may attract a bargain hunter, but book value can be consumed by losses. The Lynch category is none because the company lost money in each of the last four years. Without positive clinical data or a partner, there is no visible moat, no earnings, and no margin of safety in the Graham sense. I would watch, not celebrate.

In plain English: Bolt Biotherapeutics is a small clinical-stage company trying to develop new cancer immunotherapies, with 23 employees and no approved product. Its business looks weak: sales are almost nonexistent and it keeps losing money, including a $7.7 million loss in the quarter ended June 30, 2026. The stock trades at a low price compared with the value of its assets on the books, but because the company is burning cash, it does not look like a conventional bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer